Selective Cyclooxygenase-2 Inhibitor Rofecoxib (Vioxx) Induces Expression of Cell Cycle Arrest Genes and Slows Tumor Growth in Human Pancreatic Cancer
- 1 November 2002
- journal article
- research article
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 6 (6) , 838-844
- https://doi.org/10.1016/s1091-255x(02)00061-6
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Targeting Angiogenic Processes by Combination Rofecoxib and Ionizing RadiationAmerican Journal of Clinical Oncology, 2001
- The Tumor Suppressor ING1: Structure and FunctionExperimental Cell Research, 2001
- Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitorsCancer, 2001
- Cyclooxygenase-2 expression in human pancreatic adenocarcinomasCarcinogenesis: Integrative Cancer Research, 2000
- Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumorsJournal of Gastrointestinal Cancer, 1999
- Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs.1999
- Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.1999
- Myc suppresses induction of the growth arrest genes gadd34, gadd45, and gadd153 by DNA-damaging agentsOncogene, 1998
- The Molecular and Cellular Biology of Pancreatic CancerCritical Reviews™ in Eukaryotic Gene Expression, 1998
- Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis.1997